WPI hasn’t mentioned Lovenox to investors in a very long time, as far as I know. Lovenox has never been included in WPI’s EPS guidance for any period.
Amphastar previously sued the FDA when it didn’t get FDA approval for Lovenox, so this case could have political overtones that caught even WPI by surprise.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”